Search research articles
Contact Us
Filters
Showing results (261-270 of 328) with videos related to
Page
of 33
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 24, 2018
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma
N P Graf, P Koelblinger, N Galliker, et al.
The New England Journal of Medicine
|
October 10, 1991
A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma
G Burg, R Dummer, M Wilhelm, et al.
Melanoma Research
|
April 1, 1997
D1 dopamine receptors are not expressed in human melanoma
R Böni, W Lichtensteiger, H C Steinert, et al.
The British Journal of Dermatology
|
April 1, 1995
Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
R Böni, R A Böni, H Steinert, et al.
The Journal of Investigative Dermatology
|
January 1, 1992
Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
R Dummer, G Posseckert, F Nestle, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 16, 2008
A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up
R M Szeimies, S Ibbotson, D F Murrell, et al.
Dermatology (Basel, Switzerland)
|
January 1, 1996
Lack of expression of dopamine D2 receptors in malignant melanoma: evidence for interaction of iodobenzofurans with melanin
R Böni, H Steinert, R A Böni, et al.
Blood
|
September 1, 1996
Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease
G S Wood, D L Hardman, R Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2008
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
C Garbe, P Radny, R Linse, et al.
Oncogene
|
April 4, 2017
Sox2 is dispensable for primary melanoma and metastasis formation
S M Schaefer, C Segalada, P F Cheng, et al.
Page
of 33
Search research articles
Search
Showing results (261-270 of 328) with videos related to
Sort By:
Page
of 33
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 24, 2018
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma
N P Graf, P Koelblinger, N Galliker, et al.
The New England Journal of Medicine
|
October 10, 1991
A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma
G Burg, R Dummer, M Wilhelm, et al.
Melanoma Research
|
April 1, 1997
D1 dopamine receptors are not expressed in human melanoma
R Böni, W Lichtensteiger, H C Steinert, et al.
The British Journal of Dermatology
|
April 1, 1995
Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
R Böni, R A Böni, H Steinert, et al.
The Journal of Investigative Dermatology
|
January 1, 1992
Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
R Dummer, G Posseckert, F Nestle, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 16, 2008
A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up
R M Szeimies, S Ibbotson, D F Murrell, et al.
Dermatology (Basel, Switzerland)
|
January 1, 1996
Lack of expression of dopamine D2 receptors in malignant melanoma: evidence for interaction of iodobenzofurans with melanin
R Böni, H Steinert, R A Böni, et al.
Blood
|
September 1, 1996
Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease
G S Wood, D L Hardman, R Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2008
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
C Garbe, P Radny, R Linse, et al.
Oncogene
|
April 4, 2017
Sox2 is dispensable for primary melanoma and metastasis formation
S M Schaefer, C Segalada, P F Cheng, et al.
Page
of 33